Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026)
Scholar Rock Holding's quarterly Profit After Tax came in at -$105.5 million in Q1 2026, down 41.2% year-on-year from -$179.4 million in Q1 2025, and down 15.99% quarter-over-quarter from -$91.0 million in Q4 2025.
Scholar Rock Holding has reported Profit After Tax for 10 years, with the latest figure at -$105.5 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 41.2% year-over-year to -$105.5 million; the trailing twelve-month figure through Mar 2026 stood at -$408.7 million (down 54.72% YoY), and the FY2025 full-year result was -$377.9 million, down 53.45% from the prior year.
- Profit After Tax for Q1 2026 stood at -$105.5 million, down from -$91.0 million in the prior quarter.
- The five-year high for Profit After Tax was -$8.0 million in Q1 2022, with the low at -$110.0 million in Q2 2025.
- Average Profit After Tax over 5 years is -$60.6 million, with a median of -$56.9 million recorded in 2024.
- Year-over-year, Profit After Tax soared 71.27% in 2022 and plunged 395.33% in 2023.
- Tracing SRRK's Profit After Tax over 5 years: stood at -$39.3 million in 2022, then decreased by 17.5% to -$46.1 million in 2023, then sank by 44.07% to -$66.5 million in 2024, then tumbled by 36.88% to -$91.0 million in 2025, then fell by 15.99% to -$105.5 million in 2026.
- The last three Profit After Tax figures came in at -$105.5 million (Q1 2026), -$91.0 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -105.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.51 Mn |
| Dec 31, 2025 | -90.97 Mn |
| Sep 30, 2025 | -102.22 Mn |
| Jun 30, 2025 | -110.03 Mn |
| Mar 31, 2025 | -74.72 Mn |
| Dec 31, 2024 | -66.45 Mn |
| Sep 30, 2024 | -64.48 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -56.85 Mn |
| Dec 31, 2023 | -46.13 Mn |
| Sep 30, 2023 | -42.36 Mn |
| Jun 30, 2023 | -37.93 Mn |
| Mar 31, 2023 | -39.38 Mn |
| Dec 31, 2022 | -39.26 Mn |
| Sep 30, 2022 | -43.30 Mn |
| Jun 30, 2022 | -44.00 Mn |
| Mar 31, 2022 | -7.95 Mn |
| Dec 31, 2021 | -35.91 Mn |
| Sep 30, 2021 | -37.51 Mn |
| Jun 30, 2021 | -30.71 Mn |
| Mar 31, 2021 | -27.67 Mn |
| Dec 31, 2020 | -26.57 Mn |
| Sep 30, 2020 | -23.56 Mn |
| Jun 30, 2020 | -19.28 Mn |
| Mar 31, 2020 | -17.07 Mn |
| Dec 31, 2019 | -11.57 Mn |
| Sep 30, 2019 | -16.15 Mn |
| Jun 30, 2019 | -12.53 Mn |
| Mar 31, 2019 | -10.76 Mn |
| Dec 31, 2018 | -14.97 Mn |
| Sep 30, 2018 | -10.76 Mn |
| Jun 30, 2018 | -14.71 Mn |
| Mar 31, 2018 | -8.89 Mn |
| Dec 31, 2017 | -8.46 Mn |
| Sep 30, 2017 | -5.93 Mn |
| Jun 30, 2017 | -5.88 Mn |